Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−7.36 USD
−35.14 M USD
5.00 K USD
1.38 M
About Alaunos Therapeutics, Inc.
Sector
Industry
CEO
Dale Curtis Hogue
Website
Headquarters
Houston
Founded
2003
FIGI
BBG000FWCC57
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TCRT is 1.96 USD — it has increased by 0.49% in the past 24 hours. Watch Alaunos Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Alaunos Therapeutics, Inc. stocks are traded under the ticker TCRT.
TCRT stock has risen by 15.29% compared to the previous week, the month change is a −15.16% fall, over the last year Alaunos Therapeutics, Inc. has showed a −73.87% decrease.
TCRT reached its all-time high on Nov 10, 2015 with the price of 2,239.50 USD, and its all-time low was 1.63 USD and was reached on Dec 16, 2024. View more price dynamics on TCRT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TCRT stock is 7.08% volatile and has beta coefficient of 1.60. Track Alaunos Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Alaunos Therapeutics, Inc. there?
Today Alaunos Therapeutics, Inc. has the market capitalization of 3.14 M, it has decreased by −5.78% over the last week.
Yes, you can track Alaunos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Alaunos Therapeutics, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
TCRT net income for the last quarter is −1.13 M USD, while the quarter before that showed −1.13 M USD of net income which accounts for 0.18% change. Track more Alaunos Therapeutics, Inc. financial stats to get the full picture.
No, TCRT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 1.00 employees. See our rating of the largest employees — is Alaunos Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Alaunos Therapeutics, Inc. EBITDA is −7.17 M USD, and current EBITDA margin is −523.56 K%. See more stats in Alaunos Therapeutics, Inc. financial statements.
Like other stocks, TCRT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alaunos Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alaunos Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alaunos Therapeutics, Inc. stock shows the sell signal. See more of Alaunos Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.